Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead

Madrigal Pharmaceuticals has licensed from Arrowhead Pharmaceuticals an RNA interference candidate that targets a genetic mutation present in around 30% of patients with MASH.